Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.…
FTRE Q3 deep dive: margin gains, backlog reset, and early-phase expansion shape outlook
Fortrea Holdings (NASDAQ: FTRE) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 14,000 employees.
The shares were at 18.55 USD on 20 November 2026, up 64.9% over 52 weeks. Its 52-week range is 8.550 USD to 26.16 USD: the price is 29.1% below the high and 117.0% above the low.
Its market capitalisation is 1.79B USD.
Fortrea Holdings reports return on equity of -175.0%, an operating margin of 1.7% and revenue down 1.4% year over year.
Its debt exceeds its cash by 897.90M USD, a debt-to-equity ratio of 1.98. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 12 analysts cover the stock, with an average rating of Buy; their mean price target of 23.63 USD is 27.4% above the current price. The next earnings report is expected on 25 February 2027.